Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 04/30/18 → 04/30/21 |
Funding
- Vertex Pharmaceuticals Incorporated: $106,210.69
VX17-661-116 A Phase 3, Open Label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with Tezacaftor in Combination if Ivacaftor in Subjects with Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous f
- Goetz, Danielle (PI)
Project: Research